OS Therapies, Inc. (NYSE-A: OSTX) entered into agreements for the commercial manufacture of OST-HER2. The company is ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...
Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...
Earlier this month, Vanda Pharmaceuticals agreed to pay $10 million upfront for the license to Anaptys’ phase 3-stage pustular psoriasis drug imsidolimab.
Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this ...
Pharmaceutical Technology on MSN2d
Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drugAardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
1d
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...
Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback